Insight

Hafsa Elmarrachi: Strategic Synthesis of Breakthrough Clinical Advances in Lung and GI Cancers Presented at ASCO 2022 and 2023

Hafsa Elmarrachi/LinkedIn

Aug 3, 2025, 17:01

Hafsa Elmarrachi: Strategic Synthesis of Breakthrough Clinical Advances in Lung and GI Cancers Presented at ASCO 2022 and 2023

Hafsa Elmarrachi, Ph.D. Researcher at Mohammed VI University of Health Sciences, shared a post on X, about a recent article she and her colleagues co-authored published in Cancer Treatment and Research Communications:

“I’m proud to share our latest comprehensive review published in Cancer Treatment and Research Communications, offering a strategic synthesis of breakthrough clinical advances presented at ASCO 2022 and 2023, focused on lung and gastrointestinal cancers.

Our work highlights transformative progress, including:

Cutting-edge targeted therapies delivering promising outcomes for KRAS G12C and EGFR-mutated lung cancers,
Innovative use of ctDNA to guide adjuvant therapy decisions in stage II colon cancer, reducing overtreatment,
Exceptional 100% clinical complete response rates with immunotherapy in dMMR rectal cancer patients,
Significant survival benefits with the addition of nimotuzumab in K-RAS wild-type pancreatic cancer,
Effective combination therapies across GI cancers balancing efficacy and manageable toxicity.

By distilling these pivotal studies, our review provides clinicians and researchers with a clear roadmap to integrate the latest evidence into precision oncology—advancing personalized care and improving patient outcomes.”

Title: Advances in the Management of Lung and Gastro-Intestinal Cancers: Clinical Studies Review from ASCO 2022/2023 Annual Meetings

Authors: Hafsa Elmarrchi, Meriem Andrifi, Nabil Ismaili

Read the Full Article on Cancer Treatment and Research Communications

Hafsa Elmarrachi: Strategic Synthesis of Breakthrough Clinical Advances in Lung and GI Cancers Presented at ASCO 2022 and 2023